Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14) - Lee, C K; Chon, H J; Cheon, J (Lancet Gastroenterol Hepatol, 2023)